3B Pharmaceuticals

Executive Summary

3B Pharmaceuticals GmbH is a privately held R&D company based in Berlin, Germany, dedicated to developing targeted radiopharmaceuticals for oncology diagnostics and therapeutics. Founded in 2002, the company leverages a proprietary platform to create novel radiopharmaceuticals that combine high specificity with theranostic capabilities—enabling both imaging and therapy with the same targeting molecule. Through strategic partnerships with international pharmaceutical firms, 3B advances its pipeline toward clinical validation, focusing on cancers with high unmet medical need. The company's programs aim to improve precision medicine by delivering radiation directly to tumor cells while minimizing off-target effects. Although specific pipeline details are not publicly disclosed, 3B's expertise in radiochemistry and its collaborative approach position it as a key player in the growing radiopharmaceutical sector. With increasing investor interest in targeted radionuclide therapy, 3B Pharmaceuticals is well-placed to capitalize on emerging opportunities in oncology.

Upcoming Catalysts (preview)

• TBDAnnouncement of a new partnership or licensing deal for advanced radiopharmaceutical program70% success
• H2 2026Disclosure of preclinical data for a lead candidate in a major oncology indication60% success
• TBDSeries B or later-stage financing round to support clinical development50% success